Retarpen

Quick links to important sections

Retarpen

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Retarpen

Property Description
Active ingredient Benzathine Benzylpenicillin
Form Powder for suspension for injection (Depot)
Pharmacological class Natural Penicillin Antibiotic
General purpose Long-term protective coverage against susceptible bacteria
Origin Semi-synthetic derivative

What Type of Medicine is Retarpen? (Identity and Classification)

Retarpen, with the active component Benzathine Benzylpenicillin, is a prescription-only antibiotic medication. It is classified within the pharmacological class of Natural Penicillins, a category of Beta-Lactam Antimicrobials. The compound is considered semi-synthetic, as it is a salt derivative of the naturally occurring Penicillin G structure. This formulation is highly regarded for its clinical efficacy against a narrow spectrum of activity, predominantly targeting Gram-positive organisms and certain spirochetes, and is consistently included on the WHO Model List of Essential Medicines.


Composition and Unique Long-Acting Form

Retarpen is distinct due to its delivery system: it is supplied as a depot preparation in the form of a powder for suspension for injection, designed for exclusive intramuscular (IM) administration. The drug’s composition relies on the minimal solubility of the Benzathine salt, which creates a sustained-action release mechanism, a key differentiating feature from standard, rapid-acting penicillin salts.

Following injection, the medication establishes a localized reservoir, from which the active ingredient is slowly liberated into the bloodstream over an extended period. This long-acting feature ensures the maintenance of effective drug levels for long durations, allowing for prolonged protection from a single dose.


General Purpose and Core Benefit

The general purpose of Retarpen is to achieve the effective and complete bactericidal eradication of susceptible bacterial pathogens. This sustained physiological action allows the drug to provide long-term, protective coverage from a single dose. This core benefit is invaluable in clinical scenarios requiring prolonged coverage, such as continuous prophylaxis against recurrent rheumatic fever.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Retarpen?

Possible Side Effects and Safety Information

The official safety profile for Benzathine Benzylpenicillin (Retarpen) classifies potential adverse reactions by frequency and the body system affected, based on regulatory documentation. Allergic reactions, ranging from rash to serious anaphylaxis, are among the key safety considerations and are strictly contraindicated in individuals with a known hypersensitivity to penicillins or cephalosporins.

Regulatory Classification of Adverse Reactions

Frequency Category Examples of Officially Listed Effects (by System)
Common Gastrointestinal disorders (Nausea, Diarrhoea), Fungal infection (Candidiasis)
Uncommon Inflammation of the mouth or tongue (Stomatitis, Glossitis), Vomiting
Rare Serious allergic reactions (Anaphylactic shock), Blood disorders (Haemolytic anaemia, Thrombocytopenia)

Serious adverse reactions documented in official labeling include Severe Cutaneous Adverse Reactions (SCAR), such as Stevens-Johnson syndrome, and Neurovascular Damage that may result from improper administration. Furthermore, C. difficile-associated diarrhea (CDAD) is a serious reaction associated with antibiotic use that may occur during treatment or after cessation.

Administration and Contextual Safety Notes

The most critical safety restriction noted in regulatory texts is that the medication is for deep intramuscular injection only; inadvertent intravenous or intra-arterial administration is strictly prohibited due to the risk of severe damage, including paralysis, gangrene, or cardiac arrest. Contextual safety statements address the potential for the Jarisch-Herxheimer reaction in patients being treated for syphilis, typically occurring hours after injection, and the increased risk of toxicity, such as encephalopathy, in individuals with renal impairment.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Retarpen (Benzathine Benzylpenicillin) by its potential for acute, dose-dependent neurotoxicity. The Central Nervous System (CNS) is the primary physiological system affected. Documented overdose presentations may include neurological manifestations such as myoclonus, altered consciousness, and severe, life-threatening outcomes like convulsions and seizures. This severity necessitates rapid action.

In all cases of suspected overdose, immediate medical attention must be sought. Regulatory guidance strictly requires individuals to contact emergency services immediately if severe neurological signs, particularly seizures, are observed. Management is classified as symptomatic and supportive treatment, as no specific antidote is known for penicillin overdose. For critical cases resulting from excessively high serum concentrations, hemodialysis is an officially documented procedural option to enhance drug clearance.

A specific population-related consideration is that patients with impaired renal function carry a substantially increased risk of toxicity, including seizures, due to the drug’s compromised clearance from the body. Therefore, all symptomatic cases require hospital monitoring to manage and stabilize potential CNS effects.

Therapeutic Uses of Retarpen

What Retarpen Treats: Main Uses and Benefits

Retarpen (Benzathine Benzylpenicillin) is generally used in clinical settings to provide targeted, sustained antibiotic support and supportive relief against highly specific conditions caused by susceptible bacteria and spirochetes. Its long-acting formulation delivers a protective benefit crucial in managing chronic disease risk and supporting pathogen clearance. The medicine is used to treat certain bacterial infections and help prevent serious diseases like rheumatic fever.

This medication is commonly used to help manage symptomatic episodes in Syphilis (primary, secondary, and early latent), Yaws, Bejel, Pinta, and acute Group A Streptococcal (GAS) infections like pharyngitis and tonsillitis. Crucially, it is applied in addressing the long-term threat of recurrent Acute Rheumatic Fever (ARF) to manage the risk of damage to the heart known as Rheumatic Heart Disease (RHD).

“This protective strategy supports the patient during episodes of heightened discomfort and contributes to easing the overall symptom load during episodes of heightened discomfort.”

The primary therapeutic benefit of the sustained action may assist in providing supportive relief against recurrence and managing the risk of re-infection, which contributes to easing the overall symptom load and is commonly used to help provide primary prophylactic support against the risk of subsequent autoimmune complications.

Quick Fact: Relief for Recurrence
Supports long-term prevention of inflammatory symptoms associated with Recurrent Acute Rheumatic Fever by maintaining continuous, protective antibiotic levels.
Is commonly used to help with Systemic Imbalance caused by susceptible streptococcal infections.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Retarpen — Official Regulatory Information

Retarpen (Benzathine Benzylpenicillin) eligibility is strictly defined by regulatory documents, which establish absolute non-eligible patient groups and conditions requiring caution.


Populations for Whom Use is Contraindicated

Classification Population Status
Allergy History of hypersensitivity (allergy) to any penicillin or severe immediate beta-lactam allergy Contraindicated
Excipient Allergy Known allergy to soya or peanut (due to excipients in some formulations) Contraindicated
Injection Route Intravenous (IV) or Intra-arterial (IA) administration Prohibited

Populations Requiring Conditional or Cautious Use

Classification Population/Condition Status
Organ Function Patients with Impaired Renal or Hepatic Function Use with Caution
Allergic Risk Patients with Allergic Diathesis or Bronchial Asthma Use with Caution
Infection Site Treatment of Neurosyphilis Not Recommended

Age and Reproductive Eligibility

Use is generally permitted in adults, adolescents, children, and neonates for specific labeled indications, though dosing must be carefully managed in the young and the elderly due to potential decreased organ function. The medicine can be used during pregnancy when appropriately indicated, and is acceptable during breastfeeding with caution, as small amounts pass into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns of Retarpen (Benzathine Benzylpenicillin) as described in government regulatory documents.


Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance / Class Official Regulatory Description
Transporter-Mediated (PK) Probenecid Inhibits the renal tubular secretion of penicillin G, resulting in increased and prolonged plasma concentrations of the active component.
Pharmacodynamic (PD) Bacteriostatic Antibiotics (e.g., Tetracyclines) These agents may interfere with the bactericidal activity of penicillin, which relies on active bacterial multiplication.

Interaction-Related Restrictions and Considerations

The co-administration of Benzathine Benzylpenicillin with bacteriostatic agents is generally not recommended in regulatory guidance due to the potential for therapeutic interference and reduction of efficacy. Timing separation rules are not formally stated as mandatory for this injectable formulation.

Population-Specific Interaction Notes

Reduced kidney function (renal impairment) is officially noted as a physiological factor that affects clearance. Because the medicine is slowly eliminated in this setting, it may lead to an increased risk of accumulation and heightened systemic exposure of the active component.

Mechanism of Action

Irreversible Disruption of Bacterial Cell Wall

This domain covers the drug's core molecular action: the irreversible inhibition of Penicillin-Binding Proteins (PBPs), which are essential for building the bacterial cell wall. This mechanism initiates a physiological cascade that causes the bacteria to rupture due to osmotic pressure, leading to the bactericidal effect and the destruction of susceptible microorganisms.


Mechanism of Sustained Systemic Exposure

This domain describes the function of the unique benzathine salt formulation, which acts as a depot to ensure the slow, gradual release of the active drug into the bloodstream over an extended period. This mechanism facilitates a prolonged systemic presence, maintaining concentrations adequate to inhibit bacterial growth, which is necessary for the continuous destruction of multiplying bacteria.


Constraint by Bacterial Enzyme Inactivation

This domain addresses the drug's key mechanistic limitation: its susceptibility to beta-lactamase enzymes produced by resistant bacteria. This enzymatic breakdown of the drug's beta-lactam ring prevents the inhibition of PBPs, leading to a constraint on the drug's intended action and thus preventing the bactericidal action against those specific bacterial strains.

Dosage and Administration Information

How to Use Retarpen: Official Administration Guidelines

Retarpen (Benzathine Benzylpenicillin) is administered according to a specific protocol defined by its long-acting depot formulation. Its usage is focused on professional administration, schedules, and procedural technique as documented in clinical standards.


Administration Scope and Requirements

Instruction Official Guidelines
Route of Administration The medication is approved for Deep Intramuscular (IM) Injection Only. It is strictly forbidden for intravenous (IV), intra-arterial, or subcutaneous administration.
Preparation The product is a powder for suspension that must be reconstituted with an appropriate sterile diluent (such as Water for Injections) immediately prior to use.
Specific Technique The injection must be administered slowly and steadily into a large muscle mass, such as the upper, outer quadrant of the buttock, or the ventrogluteal site. Aspiration prior to injection is a required procedural step.

Dosing Patterns and Frequency

Usage Pattern Official Schedule and Interval
Acute/Early Infection Typically a single dose of 1,200,000 IU or 2,400,000 IU, depending on the indication.
Late Infection Multi-dose regimens often utilize 2,400,000 IU, administered once weekly for a specified number of doses (e.g., three weeks).
Long-Term Prophylaxis Used for continuous protective coverage (e.g., against recurrent rheumatic fever), administered at long intervals, typically every 3 to 4 weeks.

Population and Volume Constraints

For pediatric patients, dosing is often weight-based or determined by specific weight tiers. For large total volumes of the 2,400,000 IU dose, the suspension is typically divided and administered into two separate injection sites to ensure local tolerance and proper depot formation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Retarpen

Evidence for Use in Long-Term Rheumatic Fever Prevention

The primary research for Benzathine Benzylpenicillin examined its use in a strategy to track the recurrence of new episodes of Acute Rheumatic Fever (ARF). ARF is a condition characterized by outcomes linked to inflammatory or irritative states where researchers examined changes to the heart, known as Rheumatic Heart Disease (RHD).

Research focused on individuals, particularly children and adolescents, who had already experienced one episode of ARF. Randomized Controlled Trials (RCTs) and longitudinal observational studies were applied in research contexts. Researchers examined outcomes such as the frequency of recurrent ARF episodes and changes in heart condition. While research has explored this long-term strategy, long-term outcomes are not fully established within the evidence base. Research tracked continuous maintenance of medication levels, but consistent challenge remains with patient adherence, where subgroup findings are uncertain due to variations in injection schedule follow-through.


Evidence for Use in Treating Early Syphilis

Benzathine Benzylpenicillin was evaluated in clinical trials for treating early stages of Syphilis. This research involved Systematic reviews and RCTs enrolling adults with primary, secondary, or early latent disease. Studies monitored serological response, a lab measurement of antibody levels, serving as the main outcome used to gauge how the body responded to the therapy.

Evidence is limited in determining the precise microbiological status of some patients whose antibody levels remain low but detectable after treatment (known as a “serofast state”). Additionally, subgroup findings are uncertain concerning different treatment approaches for patients with co-existing conditions, such as those with HIV co-infection, where comparative evidence is lacking in some treatment scenarios.


Research Gaps and Unanswered Questions

Several areas related to the use of Retarpen are still uncertain. A major limitation identified in research is associated with the required injection schedule: non-adherence is a known challenge that complicates observed effectiveness in real-world settings. Research is ongoing to find better methods to improve patient follow-through. Overall, evidence quality varies across studies, and future research may help provide greater clarity on sustained outcomes and strategies for improving treatment adherence.

Key Studies & References

  1. One dose of antibiotic treats early syphilis as well as three doses: NIH-funded clinical trial shows potential to simplify treatment for early syphilis (Multicenter Randomized Controlled Trial)
  2. Secondary prophylaxis with penicillin for rheumatic fever or established rheumatic heart disease - a rapid review (Systematic Review/Rapid Review)
  3. WHO Model List of Essential Medicines (Inclusion for Syphilis and Rheumatic Fever)

Frequently Asked Questions (FAQ)

Common questions about Retarpen (FAQ)

Q: Why is Retarpen given as a deep muscle injection?

A: Retarpen is formulated as a depot preparation, which means the active medicine is suspended for slow, sustained release. Official product information emphasizes that this route is mandatory to facilitate the medication's correct absorption over time. This administration method is strictly required to minimize the risk of severe complications associated with improper routes, such as injection into a vein or artery.

Q: What are the warning signs of a serious skin reaction from Retarpen?

A: Serious skin reactions, like Stevens-Johnson syndrome, can rarely occur, sometimes weeks or even months after beginning treatment. Regulatory safety documents indicate that these serious reactions may be preceded by fever or flu-like symptoms. This is followed by a spreading rash that can develop into blisters or cause the skin to peel.

Q: What is the Jarisch-Herxheimer reaction mentioned in relation to Retarpen?

A: The Jarisch-Herxheimer reaction is a temporary, flu-like response that may be observed within 24 hours of the first injection, typically when treating specific bacterial infections like syphilis. Regulatory documents describe it as causing symptoms such as fever, chills, headache, and nausea, sometimes accompanied by a temporary worsening of existing skin lesions.

Q: Why do patients sometimes experience a temporary worsening of symptoms after the injection?

A: The temporary worsening of certain symptoms is often attributed to the Jarisch-Herxheimer reaction. This reaction is described as occurring when the antibiotic rapidly kills a large number of susceptible bacteria, leading to the temporary release of bacterial byproducts into the bloodstream.

Q: Are there official studies on the long-term effects of repeated Retarpen use?

A: The medication is used for long-term prophylaxis (prevention) of conditions like recurrent rheumatic fever. Official guidance emphasizes the preventative importance of the treatment, but notes that research on long-term outcomes and potential adverse events is continually being evaluated.

Q: Does Retarpen treat viral infections like the common cold or flu?

A: Official patient information classifies Retarpen as an antibiotic intended only to treat or prevent infections caused by bacteria. The medication is not active against viruses, and therefore, it is not used to treat conditions like the common cold or the flu.

Q: Is it normal to feel pain or soreness at the injection site for a few days?

A: Pain or soreness at the injection site is a frequently reported adverse effect. Common local reactions also include swelling, redness, or tenderness around the injection area, as noted in official safety profiles.

Q: Why do some patients report a hard lump forming where the shot was given?

A: A localized area of hardness or swelling (sometimes described as a lump) is a common local reaction following the injection. This is thought to be related to the medication's unique depot formulation, which is designed to form a reservoir for slow, sustained release of the active ingredient.

Q: Is it possible for a severe allergic reaction to happen long after the injection?

A: While the most severe allergic reaction (anaphylaxis) typically occurs immediately, other forms of serious hypersensitivity reactions, such as severe skin reactions, have been reported to develop weeks or months after starting treatment. Official reports indicate that delayed severe reactions have occurred.

Q: Can Retarpen affect or interact with oral birth control pills?

A: Official warnings indicate that the effectiveness of hormonal contraceptives, including oral birth control pills, may be reduced while using penicillins. This potential interaction is a consideration noted in official warnings.

Q: Does Retarpen interact with any common over-the-counter pain medications?

A: Regulatory-aligned documents mention that penicillins can potentially affect the body's elimination of certain medications, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like aspirin. This may lead to increased levels of the penicillin in the bloodstream, which is a known pharmacokinetic effect.

Q: What should I do if I think I missed a dose or appointment for Retarpen?

A: Official guidance emphasizes that missed or late doses of this long-acting medication can interrupt the protective effect. A failure to maintain the required drug level risks a recurrence of the underlying infection or disease requiring long-term prevention.

Q: Is it safe to drink alcohol in the days following a Retarpen injection?

A: Official warnings advise that the use of alcohol should be avoided while using this medication. Alcohol may potentially worsen or complicate the effects of certain underlying medical conditions, and may increase the chance of experiencing side effects like dizziness.

Q: Is it normal to feel dizzy or lightheaded shortly after getting the shot?

A: Dizziness or a feeling of lightheadedness (vertigo) are noted in the product's safety information as potential, though less common, side effects. Somnolence (sleepiness) has also been reported after administration.

Q: Can Retarpen cause unusual mental effects like confusion or agitation?

A: Regulatory documents note that the medication can rarely affect the nervous system. Safety information indicates that rare nervous system effects may occur, including confusion, anxiety, agitation, tremors, somnolence, and hallucinations.

Q: Does Retarpen cause changes in heart rate or blood pressure?

A: Regulatory safety information indicates that rare, serious cardiovascular events have been reported. These include abnormal heart rhythms, a sensation of a pounding heart (palpitations), and a sudden and significant drop in blood pressure (hypotension).

Q: Is a fever after the injection always a reason to call a doctor?

A: Fever after the injection may be a temporary symptom of the Jarisch-Herxheimer reaction or a sign of a more serious issue, such as a severe skin reaction or a new infection. Because fever can signal a range of conditions, official guidance emphasizes the importance of medical evaluation.

How should Retarpen be stored and disposed of?

How to Store and Dispose of Retarpen

The storage and disposal of Retarpen (Benzathine Benzylpenicillin) must strictly follow official regulatory requirements to maintain the product's stability and integrity.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature The injectable suspension must be refrigerated between 2°C and 8°C. Do not freeze the product.
Protection Store in the original package to protect the medicine from light and moisture.
Child Safety Keep out of the sight and reach of children.
Stability The suspension, once prepared from the powder, must be used immediately.

Disposal Instructions

Unused or expired Retarpen and all related waste material must be disposed of in accordance with local requirements. Needles and syringes (sharps) must not be thrown into household trash; they require specialized sharps disposal procedures. Consult official guidelines for discarding unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Retarpen found in:

A-Z Index: